The portable, weatherproof Lightwall delivers cinema-grade dynamic visuals for indoor and outdoor spaces.
BELLEVUE, Wash., April 16, 2026 /PRNewswire/ -- Govee, a global leader in smart ambient lighting, today announced the Govee Lightwall, a portable lightwall with the industry's highest LED density, purpose-built to turn any gathering — from backyard barbecues and pool parties to camping trips and birthday celebrations — into an immersive visual experience.
"Lighting should go wherever the moment takes you. With Lightwall, users can enjoy a canvas of light they can set up anywhere in minutes — making every occasion more vivid, more personal, and more colorful," said Eric Wu, CEO of Govee. "Because Life is Colorful, and the best moments deserve to look that way."
Industry-Leading 1,536-LED Array, Bringing Visuals to Life with Stunning Clarity
The Govee Lightwall packs 1,536 RGBIC LEDs into a precise 32×48 pixel grid, achieving a pixel pitch of just 1.96 inches — the highest density in its class. The result is exceptionally sharp imagery with seamless color gradients, whether displaying a complete scene from across the yard or revealing intricate details up close. Powered by a 35 FPS cinema-grade frame rate, dynamic effects stay fluid and lag-free, bringing complex animations to life with smooth, natural motion.
Go-Anywhere Portability with Weatherproof Durability, Setting Up in Minutes
Breaking free from fixed wall installations, the Lightwall features a lightweight, detachable aluminum frame that can be assembled or taken down in 10–15 minutes — no tools required. Rated IP65 for water and dust resistance, it is engineered to perform in rain or shine, making it equally at home in a living room, a backyard tent, or beside a pool. A dedicated carrying case ensures effortless transport between venues.
AI-Powered Personalization for Every Skill Level, from Beginners to Creative Experts
With over 200 preset scenes — including newly optimized effects for outdoor parties and adventures — the Lightwall is ready to set the mood right out of the box. For deeper customization, AI Lighting Bot 2.0 introduces text-to-GIF technology: simply describe an idea like "a dolphin leaping out of the sea," and the Lightwall brings it to life. Advanced creators can dive into 30-layer canvas stacking with Govee Uni-IC Control to paint with 16 million colors, turning the Lightwall into a personal light art studio.
Immersive Audio-Visual Party Experiences with Music Mode and SceneStage
The Lightwall goes beyond visuals with 10 built-in music modes that synchronize lighting patterns to any beat in real time — instantly elevating parties, game nights, and outdoor movie screenings. Combined with DreamView multi-device sync and SceneStage, users can orchestrate a fully coordinated lighting atmosphere across multiple Govee devices for a truly immersive environment.
Seamless Smart Home Integration
The Govee Lightwall connects through the Govee Home App, giving users access to the full library of scenes, DIY tools, and scheduling controls. It also supports Matter, Amazon Alexa, and Google Home, enabling hands-free voice control and integration into existing smart home ecosystems.
Pricing and Availability
The Govee Lightwall is available now at Govee.com and Amazon, priced at $449.99.
For more details about Govee, please visit govee.com.
About Govee
Govee has been revolutionizing the smart living experience since 2017, with innovative, efficient, and hassle-free ambient lighting solutions for the entire home. From living spaces and gaming setups to outdoor areas and beyond, Govee smart lighting is not just visually stunning, but transforms everyday moments into personalized and engaging lighting experiences. Embracing the idea that "Life is Colorful," Govee is committed to bringing vibrant ambient lighting to every corner of the home, to fostering connections with users on both practical and emotional levels, and to making everyday moments brighter and more enjoyable.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Govee Unveils Lightwall, the Industry's Highest LED Density Lightwall Built for Every Occasion
|
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026
SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.
Lexington Clinic Adopts Full Breast Cancer Ecosystem
Lexington Clinic, Central Kentucky's largest and oldest physician-owned multi-specialty medical group (serving more than 350 providers), has implemented Lunit's complete AI-powered breast cancer ecosystem.
The deployment spans:
- Detection with Lunit INSIGHT® Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT)
- Quality optimization with Analytics™ and Volpara® Live™
- Volumetric breast density assessment with Volpara® Scorecard™
- Risk assessment with Risk Pathways™, integrated into clinical workflows
- Mammography tracking with Patient Hub™
The implementation signals a shift toward end-to-end AI integration across the breast care continuum—from risk to detection to quality—within a single software suite.
"Our goal is to deliver the highest standard of care while keeping workflows efficient and consistent," said Angie Hall, Breast Center Manager at Lexington Clinic. "Bringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient."
Adoption Across the Americas Surpasses 330 Sites
Over the past year, Lunit has expanded to more than 330 screening sites across the Americas, supporting approximately one million screening mammograms annually.
The milestone highlights a broader industry shift: while AI validation is well established, real-world adoption at scale is now the key differentiator.
"Across the Americas, we're seeing a clear move from evaluation to enterprise-wide implementation," said Craig Hadfield, CEO of Lunit International. "Providers are moving beyond pilots into daily clinical use. Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption—where AI is delivering value in routine practice."
Real-World Clinical Impact: Radiology Consultants of Iowa
At Radiology Consultants of Iowa (RCI), one of the largest radiology groups in the state, Lunit INSIGHT DBT is already embedded in routine clinical workflows, demonstrating the impact of AI beyond the study setting.
"After six months of using AI in our daily workflow, it's become part of how we read," said Robert J. Dolan, DO, breast imaging specialist at RCI. "It gives us added confidence—especially in subtle cases—and helps ensure we don't miss what matters most."
At SBI, Dr. Dolan will review cases each day in Lunit's booth, highlighting where AI positively impacts his interpretation, giving attendees a chance to discuss real-world adoption.
FDA Clearance of Next-Generation 3D AI with Current-Prior Comparison
As providers move into routine AI use, flexibility in how algorithms are deployed is becoming increasingly important. Lunit announced that Version 1.2 of its 3D mammography algorithm has received clearance from the U.S. Food and Drug Administration (FDA).
The updated version introduces current-prior comparisons and multiple operating thresholds, enabling providers to tailor AI performance to their clinical environment.
Key enhancements include:
- Current-prior comparison (CPC) provides AI findings for the current exam and up to two prior exams
- Three selectable thresholds, supporting different sensitivity and specificity trade-offs
- Access to Volpara® Scorecard™ volumetric breast density measures along with AI scores
These updates reinforce Lunit's focus on practical usability—giving clinicians greater control over how AI is applied in daily practice.
###
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026
SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.
Lexington Clinic Adopts Full Breast Cancer Ecosystem
Lexington Clinic, Central Kentucky's largest and oldest physician-owned multi-specialty medical group (serving more than 350 providers), has implemented Lunit's complete AI-powered breast cancer ecosystem.
The deployment spans:
- Detection with Lunit INSIGHT® Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT)
- Quality optimization with Analytics™ and Volpara® Live™
- Volumetric breast density assessment with Volpara® Scorecard™
- Risk assessment with Risk Pathways™, integrated into clinical workflows
- Mammography tracking with Patient Hub™
The implementation signals a shift toward end-to-end AI integration across the breast care continuum—from risk to detection to quality—within a single software suite.
"Our goal is to deliver the highest standard of care while keeping workflows efficient and consistent," said Angie Hall, Breast Center Manager at Lexington Clinic. "Bringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient."
Adoption Across the Americas Surpasses 330 Sites
Over the past year, Lunit has expanded to more than 330 screening sites across the Americas, supporting approximately one million screening mammograms annually.
The milestone highlights a broader industry shift: while AI validation is well established, real-world adoption at scale is now the key differentiator.
"Across the Americas, we're seeing a clear move from evaluation to enterprise-wide implementation," said Craig Hadfield, CEO of Lunit International. "Providers are moving beyond pilots into daily clinical use. Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption—where AI is delivering value in routine practice."
Real-World Clinical Impact: Radiology Consultants of Iowa
At Radiology Consultants of Iowa (RCI), one of the largest radiology groups in the state, Lunit INSIGHT DBT is already embedded in routine clinical workflows, demonstrating the impact of AI beyond the study setting.
"After six months of using AI in our daily workflow, it's become part of how we read," said Robert J. Dolan, DO, breast imaging specialist at RCI. "It gives us added confidence—especially in subtle cases—and helps ensure we don't miss what matters most."
At SBI, Dr. Dolan will review cases each day in Lunit's booth, highlighting where AI positively impacts his interpretation, giving attendees a chance to discuss real-world adoption.
FDA Clearance of Next-Generation 3D AI with Current-Prior Comparison
As providers move into routine AI use, flexibility in how algorithms are deployed is becoming increasingly important. Lunit announced that Version 1.2 of its 3D mammography algorithm has received clearance from the U.S. Food and Drug Administration (FDA).
The updated version introduces current-prior comparisons and multiple operating thresholds, enabling providers to tailor AI performance to their clinical environment.
Key enhancements include:
- Current-prior comparison (CPC) provides AI findings for the current exam and up to two prior exams
- Three selectable thresholds, supporting different sensitivity and specificity trade-offs
- Access to Volpara® Scorecard™ volumetric breast density measures along with AI scores
These updates reinforce Lunit's focus on practical usability—giving clinicians greater control over how AI is applied in daily practice.
###
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice
